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Renal carcinoma is a common and aggressive malignancy whose histopathogenesis is
incompletely understood and that is largely resistant to cytotoxic chemotherapy. We present
two mouse models of kidney cancer that recapitulate the genomic alterations found in human
papillary (pRCC) and clear cell RCC (ccRCC), the most common RCC subtypes. MYC
activation results in highly penetrant pRCC tumours (MYC), while MYC activation, when
combined with Vhl and Cdkn2a (Ink4a/Arf) deletion (VIM), produce kidney tumours that
approximate human ccRCC. RNAseq of the mouse tumours demonstrate that MYC tumours
resemble Type 2 pRCC, which are known to harbour MYC activation. Furthermore, VIM
tumours more closely simulate human ccRCC. Based on their high penetrance, short latency,
and histologic fidelity, these models of papillary and clear cell RCC should be significant
contributions to the field of kidney cancer research.
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R
enal cell carcinoma (RCC) is among the most common
malignancies, with an estimated 65,000 new cases and
14,000 deaths annually in the United States1. RCC can be
subclassified into distinct histologic subtypes including clear cell
RCC (ccRCC), papillary RCC Types 1 and 2, and chromophobe
RCC2. Inherited RCC can be caused by germline mutations in
multiple genes that are linked to specific histologic subtypes.
In particular, VHL, MET, FH and FLCN genes are linked to
development of the clear cell, papillary Type 1, papillary Type 2
and chromophobe RCC subtypes, respectively2–4. Not
surprisingly, these genes are often found to be mutated in
sporadic cases of RCC as well2–6.
The genetics of ccRCC have been studied in depth4. The von
Hippel-Lindau tumour suppressor protein (pVHL) is broadly
inactivated (B80%) in sporadic ccRCC by either mutation or
promoter hypermethylation3,7 and its tumour suppressor activity
is dependent on its downregulation of the alpha subunits of the
hypoxia-inducible factor (HIFa) family of transcription factors
and in particular HIF2a (refs 8–11). In addition to mutations of
VHL, whole exome sequencing studies have defined a number of
other significantly mutated genes in ccRCC such as PBRM1,
SETD2 and BAP1, many of which are related to histone
modification or nucleosome remodelling4,5,12,13. ccRCC has a
relatively low mutation burden relative to other solid tumours14
but does have characteristic large deletions and gains of
chromosomes 3p, 14q and 5q, respectively, as well as more
focal gains and losses of 8q24 (harbouring MYC) and 9p21
(harbouring CDKN2A), respectively5,12,15.
Focal amplification of 8q24 has been demonstrated in
B15–23% of ccRCC in three independent studies and in all
studies the amplicon appears to harbour MYC5,12,15. Gain of 8q,
as assessed by classic cytogenetics, is associated with a high risk of
lymph node and distant metastases and is an independent
prognostic factor16,17. Despite this genetic evidence implicating
MYC in ccRCC pathogenesis, the role of MYC in ccRCC is
complex. Studies demonstrate that HIF2a can potentiate MYC
transcriptional activity and that MYC gene signatures are able to
define a subtype of ccRCC, while HIF1a has the potential to
oppose MYC transcriptional activity18–20.
Herein we describe the development of mouse models of
papillary and clear cell RCC, by modelling the genetic events
found in human kidney cancer. We uncover that MYC activation
is sufficient to generate papillary RCC in mice. Moreover, MYC
activation, along with Ink4a/Arf (Cdkn2a) inactivation cooperates
with Vhl loss to form clear cell RCC that is occasionally
metastatic. These GEM models represent the first tractable
models of papillary and clear cell RCC that have a predictable
latency with high penetrance. These models of papillary and clear
cell RCC should therefore be significant contributions to the field
of kidney cancer research.
Results
Kidney specific MYC activation results in papillary RCC.
Prior work has examined the role of MYC in the development of
kidney cancer by overexpressing MYC under control of the
gamma-glutamyl transferase promoter21. While the mice
developed renal tumours, they appeared to be histologically and
immunophenotypically most consistent with collecting duct
carcinomas. We generated compound mutant mice engineered
to express a doxycycline-inducible Myc transgene (Tet-O-MYC)
targeted to the renal tubule cells under control of the Ksp
promoter22,23 (Ksp-rtTA; Tet-O-MYC mice; hereafter called
‘MYC’ mice) and control animals expressing only Tet-O-MYC.
Mice were fed chow containing doxycycline starting atB8 weeks
of age to induce MYC expression and were followed for survival.
MYC mice had a significantly shortened survival relative to
controls (Fig. 1a, P¼ 0.0162) and upon necropsy were found to
harbour renal tumours but no evidence of macroscopic metastatic
disease (Fig. 1b).
Histologic examination showed that the majority of the
tumours found in the kidneys of MYC mice had either a papillary
or a more solid and infiltrative appearance. Smaller tumours
(o3mm) were predominantly papillary (Fig. 1b ‘papillary’),
while larger tumours (43mm) were either papillary or consisted
of more solid appearing tumours characterized by tightly packed
papillary structures lacking distinct fibrovascular cores (Fig. 1b
‘solid’). These larger, solid tumours were characterized by
hyperchromatic cells with a high nuclear to cytoplasmic ratio.
In addition, the cells contained nuclei with large nucleoli,
significant pleomorphism and were high grade (Supplementary
Fig. 1A). Notably, intra-tumoral foamy macrophages and
psammoma bodies (features that are commonly seen in human
papillary renal cell carcinoma) were lacking in the MYC tumours.
Papillary RCC with MYC activation has a worse prognosis.
Prior work has shown that a subset of pRCC, primarily Type 2
pRCC, is enriched for gene signatures of MYC activation and that
tumours with MYC activation have a worse overall survival24.
We confirmed and extended these findings using multiple gene
expression datasets, which revealed that pRCC tumours were
enriched for MYC activation gene signatures when compared to
normal kidney (Fig. 1c and Supplementary Fig. 1B)25. Finally,
to determine the impact of MYC activation on prognosis,
we classified TCGA KIRP tumours as MYC activated
(n¼ 23, defined as tumours with a Z score of the
PID_MYC_ACTIV_PATHWAY greater than 1.0 s.d. above the
mean) or not MYC-activated (n¼ 153). Consistent with previous
work, patients with MYC activated pRCC tumours had a
significantly worse overall survival (Fig. 1d, P¼ 1.46e–9)24.
Cell lines fromMYC mice are dependent upon MYC expression.
To better characterize the phenotype of the kidney tumours from
MYC mice we generated two cell lines from separate MYC
tumours (MYC-2927 and MYC-2983). After verifying the Dox
responsiveness of the Tet-O-Myc transgene in these MYC cells
(Fig. 1e), we examined the effect of MYC expression on cell
proliferation in vitro. MYC cells grown in the presence of Dox
(activated MYC) had increased proliferation at 4 days (Fig. 1f),
as well as a visible increase in cell number (Fig. 1g). In addition,
whileMYC cells without Dox were unable to form colonies in soft
agar, MYC cells grown in Dox formed colonies robustly in an
anchorage independent manner (Fig. 1h). Finally, we assessed the
ability of MYC-2983 cells to form tumours in vivo and their
in vivo growth dependence on MYC expression. To this end,
5 106 MYC-2983 cells were injected subcutaneously and
monitored for growth in mice fed Dox chow. Once tumours
reachedB300mm3, mice were either continued on or withdrawn
from Dox (Fig. 1i). As expected, tumours of mice that remained
on Dox continued to have rapid growth, while tumours in
mice withdrawn from Dox remained dormant. Therefore,
MYC-induced papillary RCCs are dependent upon MYC
expression for in vitro and in vivo growth.
Vhl loss with MYC activation promotes clear cell changes.
Focal amplification of 8q24 is found in 15% of ccRCC in the
TCGA KIRC data set5. To ensure that MYC was located in
the minimal common region (MCR) of amplification, we used
GISTIC 2.0 analysis to identify a broad statistically significant
(q valueo0.25) region of amplification on chr8. This
MCR contains MYC. A plot of mean gene-level DNA copy
number measurement by genomic position (Supplementary Data
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15770
2 NATURE COMMUNICATIONS | 8:15770 | DOI: 10.1038/ncomms15770 | www.nature.com/naturecommunications
a b
PID_MYC_PATHWAY
PID_MYC
ACTIV_PATHWAY
DANG_MYC
TARGETS_UP
ES: 0.57
P value: 0.008 
ES: 0.54
P value: 0.027 
ES: 0.66
P value: 0.008 
c
d
e
h MYC-2983
Dox – +
IB: c-Myc
IB: Vinculin
100 kDa
50 kDa
0 20 40 60
20
40
60
80
100
MYC
Control
P = 0.0162
Pe
rc
en
t a
liv
e
Weeks
g
Pa
pi
lla
ry
So
lid
H&EGross
i
0 20 40 60 80 100
Months
Non−MYC Activated
MYC Activated
P=1.46e−9
0
10
20
30
40
50
60
70
80
90
100
f
Ve
hi
cl
e
D
ox
MYC-2983MYC-2927
Ve
hi
cl
e
D
ox
MYC-2927
0
2
4
6
8
Vehicle
Dox 2 µg ml–1
IB: c-Myc
IB: Ku80
50 kDa
– +
MYC-2927 MYC-2983
0 1 2 3 4
0
20
40
60
80
*
*
***
***
***
***
******
***
***
Days
0 1 2 3 4
Days
R
el
at
iv
e 
vi
ab
ilit
y
R
el
at
iv
e 
vi
ab
ilit
y
Ve
hic
le
Do
x
Ve
hic
le
Do
x
0
50
100
150
MYC-2927 MYC-2983
# 
of
 c
ol
on
ie
s
40 60 80 100 120
0
1,000
2,000
3,000
4,000
Doxycycline diet
Regular diet
Av
er
ag
e 
tu
m
ou
r v
ol
um
e
(m
m3
)
Dox
MYC-2927 MYC-2983
MYC-2983
0
75 kDa
Days post assignment
Survival of TCGA KIRP
Pe
rc
en
t s
ur
vi
va
l
Figure 1 | Kidney specific MYC activation results in papillary renal cell carcinoma. (a) Kaplan–Meier curve showing reduced survival rates in MYC mice
(n¼ 15) compared to controls (n¼ 17) Log Rank P¼0.0162. (b) Representative gross images and photomicrographs of H&E stained kidney sections from
MYC mice (B32 weeks post Dox treatment) revealed both papillary (top panels) and solid kidney tumours (bottom panels) (scale bar, 100mm). (c) GSEA
enrichment plots showing papillary kidney tumours are enriched for multiple gene sets representing MYC activation relative to normal kidney (GSE11151).
(d) Kaplan–Meier curve of patients from the TCGA KIRP dataset demonstrating tumours with high MYC activity have reduced survival in patients with
papillary renal cell carcinomas, Log Rank P¼ 1.46e–9. (e) Immunoblot using whole cell lysates from MYC kidney tumor-derived cell lines (MYC-2927 and
MYC-2983) shows expression of MYC is Dox dependent. (f) Cell viability assay show reduced proliferation fromMYC-2927 and MYC-2983 cells upon Dox
removal. Cells grown on Dox or vehicle were analysed in replicates of n¼8 each day. (g) Bright field image of MYC-2927 and MYC-2983 cells on day 3
after being cultured with or without Dox. (scale bar, 100 mm). (h) Soft agar assays show anchorage independent growth of MYC-2927 and MYC-2983 cells
is significantly reduced upon removal of Dox. Images are representative of each condition performed in triplicate. (i) Results from xenograft studies
showing tumours formed from MYC-2983 cells remain dormant upon removal of Dox in vivo (n¼ 5 per group). (f,g) *Po0.05, ***Po0.0001.
(f,h,i) Data are presented as mean ±s.e.m. (f,h) P values obtained from student t-test.
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1 and Supplementary Fig. 2A) shows that mean MYC copy
number is larger than the 70% of the mean gene-level DNA copy
values. Therefore, while these data suggest that MYC is an
important target of amplification in this region there are still
B100 genes with mean copy number values that are higher.
Similarly, focal loss of 9p21 was found in 32% of ccRCC in the
TCGA KIRC data set5. GISTIC 2.0 analysis demonstrated the
presence of only three genes in the minimal common region
of copy number loss, CDKN2A, CDKN2B and C9orf53
(Supplementary Fig. 2B). These results suggest that both MYC
and CDKN2Amay be involved in the development or progression
of ccRCC.
To model the interplay of genomic events observed in human
RCC, we next examined the phenotypes of kidney specific Vhl
inactivation in combination with MYC overexpression or
combined MYC overexpression and Ink/Arf deletion. Specifically,
MYC mice were crossed to conditional Vhl knock-out mice
(VhlF/F)26, Cdkn2a (Ink4a/Arf / ) germline knock-out mice27,
as well as mice expressing tamoxifen-inducible Cre recombinase
under control of the Ksp cadherin promoter (KspCreERT2) to
generate cohorts of KspCreERT2; VhlF/F control mice (conditional
inactivation of Vhl, hereafter called V), KspCreERT2; VhlF/F;
Ksp-rtTA; Tet-O-Myc (conditional inactivation of Vhl and
Dox-inducible MYC overexpression, hereafter called VM),
and KspCreERT2; VhlF/F; Ink/Arf / ; Ksp-rtTA; Tet-O-Myc
(conditional inactivation of Vhl, germline Ink/Arf / , and
Dox inducible MYC overexpression, hereafter called VIM)
(see Supplementary Table 1).
Cohorts of V, VM, and VIM mice were followed for survival
(Fig. 2a). VM mice had a significantly worse survival than V mice
(P¼ 0.007) and VIM mice had a significantly worse survival than
both V and VM mice (both Po0.001, Fig. 2a). Histologic
examination showed that the kidneys of V mice were essentially
normal (Fig. 2b). In contrast, kidneys from VM and VIM mice
had a high incidence of tumour formation (67% and 100%
respectively, Table 1). Kidney tumours of VM mice had either a
tubulo-papillary or solid appearance with intervening vessels. The
tumour cells were hyperchromatic compared to the normal renal
tubular epithelium. Occasional clear cell features were identified
(Fig. 2b; Supplementary Fig. 3). Small tumours were generally
well demarcated, while larger tumours showed a multilobulated
growth pattern with frequent necrosis, haemorrhage and
dystrophic calcifications (Supplementary Fig. 4A).
While tumours similar to those seen in the VM mice were
observed in VIM mice, the kidneys of VIM mice also harboured
tumours with a solid or tightly packed tubulo-papillary
appearance. The cells were small to intermediate in size with
increased nuclear to cytoplasmic ratio with nuclei that were
round to oval with prominent single nucleoli (Supplementary
Fig. 3). Clear cell changes within the larger tumours were also
present with areas within some tumours showing what appeared
to be histology strikingly similar to human ccRCC (Fig. 2b).
These areas were typified by nests of tumour cells with an
increased amount of clear to granular cytoplasm, separated by
thin vascular channels. Therefore, while Vhl loss combined with
MYC activation is sufficient to induce modest clear cell changes,
Vhl loss combined with MYC activation and Ink/Arf deletion
induces bona fide clear cell RCC (Table 1).
ccRCC with VM and VIM alterations have worse prognosis. We
next examined whether human ccRCC tumours with similar
genomic characteristics (VHL inactivation; VHL inactivation and
MYC activation; and VHL inactivation, CDKN2A loss and MYC
activation) have similar outcomes as those seen in our mouse
models. Of TCGA KIRC tumours (n¼ 525), 87, 13 and 31% had
VHL inactivation, MYC activation and CDKN2A deletion,
respectively (Fig. 2c). We further classified these patients as V
(n¼ 286, 54%), VM (n¼ 26, 5%) and VIM (n¼ 32, 6.1%) and
noted that VM and VIM patients had a significantly decreased
survival relative to V patients (P¼ 0.005 and P¼ 5.086 10 9,
respectively (Fig. 2d), but that VM and VIM patients had a similar
overall survival. In keeping with the notion that VIM tumours are
more clinically aggressive, we also noted significant enrichment of
higher stage and presence of metastases in patients with VIM
tumours relative to patients with V tumours (Fig. 2e,f). When
limiting our analysis to stage IV tumours, we did not see sig-
nificant survival differences by genotype (V, VM and VIM)
(Supplementary Fig. 5). Because of the very limited patient
numbers (V¼ 28, VM¼ 7 and VIM¼ 11), we examined whether
VIM genotype was prognostic when controlled for both TNM
stage and Furhman grade. Cox proportional hazards (Cox PH)
modelling using the V genotype as the reference demonstrated
that the VIM genotype was still prognostic (Cox PH¼ 1.79,
P¼ 0.034). Therefore, VIM tumours appear to have worse clinical
characteristics and outcome in human ccRCC patients even when
controlling for stage and grade.
Finally, we attempted to assess whether VHL loss, CDKN2A
loss and MYC activation are dysregulated at tumour initiation or
tumour progression, by analysing their relative frequency by
TNM stage in the TCGA KIRC data set (Fig. 2g). We found that
the rate of VHL inactivation was relatively similar across
all stages, while the rate of CDKN2A loss and MYC
activation appeared to increase with TNM stage. This data are
consistent with the known role of VHL as a gatekeeper tumour
suppressor gene and suggests that CDKN2A loss and MYC
activation are events involved in the progression of a subset of
ccRCC tumours.
VM and VIM cell lines are dependent upon MYC expression.
We generated cell lines from VM and VIM tumours to assess
their dependency on MYC expression. We first confirmed the
Dox inducibility of the MYC transgene in these VM (2849 and
3055) and VIM (3039 and 3131) cells (Fig. 3a), as well as the fact
that they had undergone Cre mediated recombination of the
Vhl locus (Supplementary Fig. 4B). Furthermore, we set out to
confirm that VM-3055 and VIM-3039 cell lines are epithelial in
nature. We performed RNAseq and co-clustered mouse 3T3
fibroblasts with VM-3055 and VIM-3039 cell lines using the top
10% of the most differentially expressed genes (Supplementary
Fig. 4C). 3T3 fibroblasts show a distinctly different expression
pattern from both VM-3055 and VIM-3039 cell lines showing
that our VM and VIM cell lines are not fibroblastic in nature.
After confirming that the VM and VIM cells were derived from
renal epithelium, we assessed their growth in in vitro
assays. Similar to MYC cells, the proliferation and anchorage
independent growth of VM and VIM cells were dependent on
MYC expression (Fig. 3b–d).
To understand the MYC dependent changes on the
transcriptomes of VM-3055 and VIM-3039 cells, we performed
RNAseq on these cells grown in tissue culture in the presence or
absence of Dox. There were a large number of genes that
were differentially regulated (increased or decreased greater than
two-fold; t-test FDRo0.05) by MYC activation (Dox) in both
VM-3055 (799 up and 2491 down) and VIM-3039 (1017 up and
2159 down) cells (Fig. 3e). While there was overlap among genes
that were upregulated by Dox in both VM-3055 (634 of 799) and
VIM-3039 cells (634 of 1017) (Fig. 3e), nearly a third of Dox
inducible genes in VIM-3039 cells (378 of 1017) were not
upregulated in VM-3055 cells. A similar percentage of genes
repressed by MYC activation (Dox) in VIM-3039 cells were not
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repressed in VM-3055 cells either, suggesting that MYC may
regulate both an overlapping and a unique spectrum of genes in
VM-3055 and VIM-3039 cells.
We next performed gene set analysis. Gene sets that were
enriched in VM-3055 cells cultured in Dox relative to those
cultured without Dox included a number of gene signatures
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characteristic of MYC activation including those related to cell
cycle progression and ribosome biogenesis (Supplementary
Data 2). A parallel analysis in VIM-3039 cells also demonstrated
high enrichment in proliferation and ribosome biogenesis gene
signatures (Supplementary Data 3), but also included gene
signatures related to DNA methylation, as well as RNA binding.
Indeed, the top gene signatures significantly enriched in VM-3055
and VIM-3039 cells (an area under the curve (AUC) greater than
0.25) were relatively non-overlapping (Fig. 3f). While these
findings are in keeping with the notion that MYC activation
induces many unique gene expression changes specific to
VM-3055 and VIM-3039 cells given the analysis is on a
single-cell line, they will need to be validated in future studies.
GEM tumours correlate with human RCC. Given that MYC
tumours resemble human papillary tumours histologically, while
VM and VIM tumours resemble ccRCC, we wanted to determine
if the similarities would also be apparent at the gene expression
level. Pearson correlations on whole transcriptome centroids
between MYC (n¼ 4), VM (n¼ 4) and VIM (n¼ 4) mouse
tumours and the TCGA KIRC and KIRP data revealed that VM
and VIM tumours correlated most highly with TCGA KIRC
tumours, whileMYC tumours correlated more highly with TCGA
KIRP tumours (Fig. 4a). Further verifying the importance of
MYC activity in pRCC Type 2, a cross species analysis of mouse
MYC tumours with the TCGA KIRP data set demonstrated
co-clustering of MYC tumours with human papillary Type 2
tumours (Fig. 4b). Moreover, transcriptome wide Pearson
correlations revealed that MYC tumours more closely resemble
TCGA KIRP tumours verified to be Type 2 pRCC (Fig. 4c).
Collectively, these analyses support the clinical relevance of the
MYC, VM and VIM mouse models with human papillary and
clear cell renal cancers.
Ink4a/Arf loss in VM mice promotes metastases. During
necropsies of VIM mice, we noted that a number of mice had
what appeared to be macroscopic metastases to the liver at a low
frequency (Fig. 5a,b, and Table 1). Histologically, the liver
metastases were either tubulo-solid or clear cell with cytologic
features consistent with the primary renal tumour. Metastases
were identified in the subcapsular area and within the
parenchyma. Notably, vascular spaces were involved by tumour
in some of the liver specimens (Fig. 5a). We did not see any
macroscopic metastases to other organs such as the lung.
Given the metastatic phenotype seen in the VIM mice but not
in the VM mice, we examined a panel of genes that characterize
epithelial to mesenchymal transition (EMT) (Cdh1 (E-cadherin),
Cdh2 (N-cadherin), Vim (vimentin)), as well as a panel of
transcription factors well known to regulate EMT (Snai1, Snai2,
Zeb1, Zeb2, Twist1) in the RNAseq data from our cell lines.
VIM-3039 cells demonstrated gene expression changes that were
consistent with a state of EMT with decreased expression of
E-cadherin (Cdh1) and increased expression of N-cadherin
(Cdh2) and Vimentin (Vim) as well as upregulated expression
of Snai1, Snai2, Twist1, Zeb1 and Zeb2 (Fig. 5c). In addition,
we noted that a number of the most differentially expressed genes
(Supplementary Data 4) are implicated in invasion and metastasis
through remodelling of the extracellular matrix such as the lysyl
oxidase family members Lox, Loxl1, Loxl2 and hyaluronan
synthase 2 (Has2) (Fig. 5d)28–32. Given these differences in
gene expression, we examined the invasiveness of our VM-3055
and VIM-3039 cell lines in vitro in matrigel invasion assays.
As predicted, VIM-3039 cells had significantly increased matrigel
invasion (Fig. 5e). Therefore, Ink4a/Arf inactivation appears to
facilitate EMT, invasion and metastases and the metastatic
phenotype seen in vivo is recapitulated in vitro.
VHL restoration has no effect on VIM cells. Previous work in
human ccRCC cell lines has shown that VHL does not affect
in vitro proliferation or anchorage independent growth33.
To assess whether this was true in our VIM cell lines, we
established isogenic VIM cells expressing eGFP or HA-VHL
(Fig. 6a). As predicted, there were no VHL dependent differences
in in vitro growth (Fig. 6b) or ability to form colonies in soft agar
(Fig. 6c). These results are in keeping with those seen in human
ccRCC cell lines. At this time we have not been able to reliably
generate allograft tumours from our VM or VIM cell lines and
therefore cannot interrogate whether VHL plays a tumour
suppressor role in vivo, as previously shown with human RCC
cell lines33. Therefore, whether our GEM models are overdriven
remains a possibility.
Discussion
The development of GEM models of cancer has had significant
impact on functional genomics as well as preclinical development
of novel therapies34,35. Indeed, robust GEMMs of non-small cell
lung cancer36 and pancreatic ductal adenocarcinoma37 have led
to an explosion of research into the biology underlying these
diseases and facilitated the study of diverse fields such as
biomarker discovery and investigations into the cell of origin of
various cancers. Our own studies highlight the role of MYC in
renal tumorigenesis and demonstrate that MYC activation is
sufficient to generate papillary RCC and that when combined
with Vhl and Ink4a/Arf inactivation results in bona fide clear cell
renal cell carcinoma.
Development of robust GEM models of kidney cancer has been
a long-sought after and elusive goal despite substantial efforts
in this area. Multiple groups have now demonstrated that Vhl
inactivation either in the germline or by conditional inactivation
in the kidney results in only a mild increase in rate of renal cyst
formation26,38–41. While the addition of secondary genetic events
such as Pten or Kif3a loss appear to accelerate the cystic
phenotype induced by Vhl inactivation, they do not result in
frank neoplasia42,43. Combined inactivation of Vhl with Trp53
does appear to induce renal tumours, which have clear cell
changes but not bona fide clear cell RCC histology44. A recent
report demonstrated that combined inactivation of Vhl with Bap1
results in renal tumours with clear cell histology45. However,
while inactivation of other tumour suppressor genes such as Flcn,
Tsc1 or Fh results in renal carcinomas46–50, they are rarely of the
clear cell histologic subtype and they exhibit long latency,
impacting their utility for routine investigation. Therefore, there
remains a need for RCC models that are highly penetrant,
relatively rapid and that display robust papillary or clear cell
histology.
Table 1 | Comparison of VM and VIM mice.
VM VIM
Median survival (weeks after Tam/Dox) 57 29.5
Cysts present 9/9 (100%) 6/6 (100%)
Kidney tumour present 6/9 (67%) 6/6 (100%)
Large kidney tumour (43mm) 2/9 (22%) 4/6 (67%)
Low grade 3/9 (33%) 1/6 (17%)
High grade 3/9 (33%) 5/6 (83%)
Necrosis present 1/9 (11%) 4/6 (67%)
Bona fide clear cell histology 0/9 (0%) 5/6 (83%)
Liver metastases 0/9 (0%) 2/6 (33%)
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15770
6 NATURE COMMUNICATIONS | 8:15770 | DOI: 10.1038/ncomms15770 | www.nature.com/naturecommunications
Schroff and colleagues recently reported the phenotype of
kidney specific overexpression of c-MYC in mice21. They found
robust development of renal tumours that were dependent on
upregulated glutaminolysis. Histological and immunohistochemical
analysis demonstrated that these tumours were most consistent
with collecting duct carcinomas. Collecting duct carcinomas
are thought to arise from the collecting ducts, which are
embryologically derived from the metanephros and distinct
from the nephron. In support of this, the immunophenotype,
as well as response to therapy are closely associated with
urothelial carcinomas (bladder cancer)51 and as such, they are
treated with bladder cancer specific chemotherapy regimens such
as MVAC (methotrexate, vinblastine, adriamycin, and cisplatin).
Our studies also examined the phenotype of kidney specific
overexpression of c-MYC. However, in contrast to Schroff and
colleagues our MYC mice developed renal tumours with histology
highly reminiscent of human papillary RCC. We hypothesize that
these distinctions may be due to the relative differences in
expression patterns of the promoters used to overexpress MYC
(Schroff et al. use g-glutamyl transpeptidase while our studies use
a b
c
d
IB: c-Myc
IB: Ku80 
e fGenes 
378
6340
0
0
00
4
602 0
0
933
5
1,553
161
VIM Dox UP VM Dox UP
VIM Dox DOWN VM Dox DOWN
0 4
0
10
20
30
Days
0 1 2 3 4
0
10
20
30
40
50
***
***
***
0
5
10
15
20
25
***
***
***
***
D
ox
Ve
hi
cl
e
D
ox
Ve
hi
cl
e
1 2 3
***
***
***
***
0 21 3 4
0
50
100
Days
***
***
***
Vehicle
Dox
Days
0 41 2 3
Days
IB: c-Myc
Dox
Dox
Gene signatures
34 129 71
D
ox
Ve
hi
cl
e
Ve
hic
le Do
x
Ve
hic
le Do
x
0
50
100
# 
of
 c
ol
on
ie
s
***
***
100
150
200
0
50#
 o
f c
ol
on
ie
s
Do
x
Do
x
Ve
hic
le
Ve
hic
le
VM-2983 VM-3055
***
***
VM-2849 VM-3055
– –
– –+ +
+ +
VIM-3039 VIM-3131
VM-2849 VM-3055 VIM-3039 VIM-3131
VM-2849 VM-3055 VIM-3039 VIM-3131
R
el
at
iv
e 
vi
ab
ilit
y
VM-2849 VM-3055 VIM-3039 VIM-3131
R
el
at
iv
e 
vi
ab
ilit
y
R
el
at
iv
e 
vi
ab
ilit
y
R
el
at
iv
e 
vi
ab
ilit
y
IB: Ku80 
VIM-3039 VIM-3131
75 kDa
50 kDa
75 kDa
50 kDa
VM Enriched VIM Enriched
Figure 3 | VM and VIM tumours are dependent on MYC expression. (a) Immunoblot of whole cell lysates from VM (VM-2849 and VM-3055) and VIM
(VIM-3039 and VIM-3131) tumour-derived cell lines shows expression of MYC is Dox dependent. (b) Proliferation of VM and VIM cells is significantly
reduced with removal of Dox. Cells grown on Dox or vehicle were analysed in replicates of n¼ 8 each day. (c) Bright field image of VM and VIM cells three
days after Dox removal show a decrease in cell number (scale bar, 100mM). (d) Soft agar assays show anchorage independent growth of VM and VIM cells
is reduced upon Dox removal. Images are representative of each condition performed in triplicate. (e) Venn diagram showing overlapping and distinct sets
of genes altered upon Dox removal in VM-3055 and VIM-3039 cells. (f) Venn diagram showing Dox dependent gene expression in VM-3055 and
VIM-3039 activates distinct gene sets. (b,d) ***Po0.0001. P values obtained from student t-test. Data are presented as mean ±s.e.m.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15770 ARTICLE
NATURE COMMUNICATIONS | 8:15770 | DOI: 10.1038/ncomms15770 |www.nature.com/naturecommunications 7
Ksp-cadherin), as well as any potential differences in the timing
of MYC activation.
Our mouse models of pRCC and ccRCC faithfully recapitulate
the genomics of human RCC although the incidence of ccRCC
tumours that have coincident VHL and CDKN2A inactivation,
along with MYC activation is only B6%. The genomics of
papillary and clear cell RCC implicate MYC as a potential
oncogenic driver event5,12,15 and our studies firmly place MYC as
playing an active role in their pathogenesis. VHL inactivation
results in the stabilization of the alpha subunits of the
hypoxia-inducible factor alpha (HIF) family of transcription
factors of which HIF2a is thought to be a key oncogenic driver of
ccRCC tumorigenesis, while emerging evidence suggests that
HIF1a may be a tumour suppressor gene3,8,10,11,52,53. Past work
examining the potential interaction between HIFa subunits
and MYC suggest that while HIF1a disrupts MYC
transcriptional activity, particularly of those genes involved in
cell cycle progression, HIF2a actually facilitates MYC/MAX
interactions18,19,54. It will be interesting to determine whether
these HIF and MYC interactions occur in vivo in our VM and
VIM mouse models and whether these oncogenic dependencies
can be used as therapeutic vulnerabilities.
The Ink4a/Arf locus is best known as a cell autonomous barrier
to cellular transformation through its negative regulation of cell
cycle progression and its ability to promote cellular senescence55.
Our studies demonstrate that Ink4a/Arf inactivation promotes
liver metastases in an autochthonous ccRCC GEM model and
that Ink4a/Arf loss is associated with gene expression patterns of
EMT. Several past studies support that Ink4a/Arf may regulate
EMT and metastasis. For example, in the mid 1990s, Allan
Balmain and colleagues noted that p16 loss was a critical event in
the regulation of an invasive spindle cell phenotype of mouse
skin carcinomas, which today would likely be termed EMT56.
In addition, a recent genome wide CRISPR screen in a cell
line xenograft model identified CDKN2A as strongly associated
with increased metastases57. At this time we hypothesize that
Ink4a/Arf loss does not directly regulate EMT or metastases but
that its loss is permissive for the emergence of clones that allow
metastatic behaviour. Nonetheless, our studies bolster the notion
that Ink4a/Arf loss is a metastatic driver event and demonstrate
this association in autochthonous ccRCC GEM models.
In summary, we present GEM models of papillary and clear
cell RCC that are faithful to the genomic events and recapitulate
the histology seen in their respective human correlates. These
pRCC and ccRCC GEM models should be a valuable contribution
to the field of kidney cancer research and given their immune
competent state should be invaluable in the development of
immune based therapy.
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Methods
GEM Models. Conditional Vhl knock-out mice (VhlF/F)26, germline Cdkn2a
(Ink4a/Arf) knockout mice (Ink4a/Arf / ) (ref. 27), KspCad-CreERT2 (ref. 58),
KspCad-rtTA58 and Tet-O-Myc mice22 have all been previously described.
Tet-O-Myc was a generous gift from Dr Dean Felsher. Protocols for all animal
experiments described were approved by the UNC-CH Institutional Animal Care
and Use Committee.
Reagents for in vivo studies. Conditional activation of cre recombinase was
induced by oral administration of tamoxifen (Sigma T5648). Per ml of in vivo oral
delivery, tamoxifen was formulated as: 100mg of tamoxifen dissolved in 100 ml
100% EtOH, followed by the addition of 1ml of sunflower oil to achieve
100mgml 1. The solution was sonicated in a water bath sonicator located at 4 C
for 10-s pulses. The solution was then placed in a water bath at 50 C for 1min
until clear. Sonication and water bath steps were repeated until no particulates were
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noticeable. Animals were given 50 ml (5mg per day) for three consecutive days by
oral gavage. Tamoxifen oral solution was aliquoted and stored at  20 C and
brought to administrable solution by 50 C water bath for no longer than 5min.
The Tet-ON conditional system was activated with doxycycline chow (Research
Diets, Inc. C11300–2000 with 2,000 p.p.m. doxycycline) 7 days post oral
tamoxifen administration.
Primary tumour cell line generation and culture conditions. Primary renal
GEMM tumours were excised and washed in a solution of Pen-Strep, PBS
solution (1:1). In sterile conditions, primary tumours were cut into 2 2mm
fragments and dissociated in a gentleMACS C-Tube (Miltenyi Biotec) using the
gentleMACs Dissociator (program: m_imp Tumor_02) in 5ml of 1XDMEM,
10% FBS, 1% PenStrep. 100ml of collagenase D/dispase II (Roche: 40mgml 1) was
added to the tumour fragments and continuously inverted for 30min at 37 C.
Fragments were then subjected to a second round of dissociation using the
gentleMACS Dissociator (program: m_imp Tumor_03). A total of 5ml of
protein extraction buffer (PEB: buffer 0.5% FBS, 2mM EDTA in PBS) was
added to the dissociated fragments and resuspended by pipetting. The cell
suspension was transferred to a 50ml conical tube through a 40 mm nylon
mesh sterile cell strainer (Fisher). An additional 20ml of PEB buffer was added
to the cell suspension and then centrifuged at 300g for 5min. Supernatant
was removed and cell pellet was resuspended in 6ml of ‘conditioned media’59
containing 2 mgml 1 doxycycline (Sigma) and placed in a 6 cm sterile cell culture
plate.On reaching confluency, cells were split and cultured in 1XDMEM, 10% FBS,
1%PS containing 2 mgml 1 doxycycline. In vitro doxycyline was dissolved in
DMSO.
Xenograft. Primary renal GEMM tumour cell lines were implanted
subcutaneously into SCID mice flanks at 5 106 cells in 200 ml of PBS containing
2 mgml 1 doxycycline. To maintain expression of c-MYC, SCID mice harbouring
xenografts were placed on doxycycline chow and withdrawn from doxycycline at
the indicated times.
Immunoblotting conditions. Cells were lysed in RIPA buffer complemented
with Set I and Set II phosphatase inhibitors at 1 (Calbiochem), and protease
inhibitors at 1 (Roche). Whole cell lysate concentration was determined with
Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad). Proteins were resolved
on SDS–PAGE gels and electrotransferred to nitrocellulose membranes, 0.2 mm
(Bio-Rad). For detection of c-MYC protein, proteins were electrotransferred onto
PVDF membranes (Millipore). Primary antibodies, c-Myc (1:1,000; SC-42), VHL
(1:500; SC-5575), Ku80 (1:1,000; Cell Signaling #2,180), Vinculin-HRP (1:1,000;
Cell Signaling #18799); SC: Santa Cruz Inc. (Supplementary Fig. 6).
Cell viability assay. Cell viability in the context of the various culture conditions
was measured by CellTiter-Glo Luminescent Cell Viability Assay (Promega) per
manufacture’s protocol. Cells were counted and in a 96 well opaque side/clear
bottom cell culture plates (Corning). Luminescence measurements were captured
using a Biotek Synergy 2 plate reader. Statistical significance was measured by
student t-test.
Soft agar assay. Anchorage independent growth was assayed following a standard
soft agar assay protocol (bottom layer, 0.6% Difco Noble Agar (BD Biosciences)
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and top layer 0.4% Noble agar (Difco)). 200ml of control media or media
containing 2 mgml 1 doxycycline was added to hydrate top agar every 72 h. A total
of 5,000 cells were plated in each well of a tissue culture treated 6 well
plate (Corning). Colonies were stained with crystal violet solution for 4 h and
destained with H2O. Pictures were taken using a digital camera (Cannon).
Treatment conditions were performed in triplicate. Statistical significance was
measured by t-test.
Mouse RNAseq. An equal number of cells (2 105 cells per dish) were plated
with or without Dox and collected for RNA 24 h later. RNA was isolated and
purified for RNAseq analysis using the RNeasy Mini Kit (Qiagen) following
manufacturer’s protocol and eluted in water. A total of 200–1,000 ng of total RNA
was used to prepare libraries with the TruSeq Stranded mRNA Sample Prep Kit
(Illumina). Around 75b paired-end reads were sequenced on a NextSeq 500
Desktop Sequencer using a high output flow cell kit (Illumina), yielding an average
of over 28M reads per sample. QC-passed reads were aligned to the mouse
reference genome (mm9) using MapSplice60. The alignment profile was
determined by Picard Tools v1.64 (http://broadinstitute.github.io/picard/). Aligned
reads were sorted and indexed using SAMtools and translated to transcriptome
coordinates then filtered for indels, large inserts and zero mapping quality using
UBU v1.0 (https://github.com/mozack/ubu). Transcript abundance estimates
for each sample were performed using RSEM, an expectation-maximization
algorithm (Li and Dewey, 2011) using the UCSC knownGene transcript and gene
definitions61. Raw RSEM read counts for all RNAseq samples were normalized to
the overall upper quartile62.
Gene set analysis was performed between two groups of samples by first ranking
all genes by t-statistic between groups. A K–S test was performed to determine if
the genes in each gene set from MSigDB were uniformly distributed among the
ranked list. K–S test P values were corrected via B–H procedure with an overall
FDR of 5%. ROC curves were then generated for each gene set using the ranked list
of t-statistics, and the AUC for the top 10% of ranked genes was used to rank gene
sets among those passing the K–S test.
Analysis of human renal gene expression data from TCGA. GSE11151 data set
was downloaded on Jan 27, 2015 from Gene Expression Omnibus (GEO) website.
RNA Expression dataset was log2-transformed/median centred across pRCC and
normal tissue samples. RNA expression dataset was analysed with the Gene Set
Enrichment Analysis (GSEA) desktop platform.
TCGA KIRP dataset was downloaded on Feb 1, 2015 from Broad TCGA
website. RNA Expression dataset was log2-transformed/median centred.
RNA expression data set was analysed with the GSEA desktop platform.
TCGA KIRC data sets were downloaded on Feb 15, 2015 from Broad TCGA
website. RNA Expression dataset was log2-transformed/median centred. RNA
expression dataset was analysed with the cBioPortal Oncoprint function and on
R platforms.
Analysis of human copy number data from TCGA. Gene-level segmented
DNA copy values for the TCGA KIRC cohort (n¼ 528) were downloaded from
the Broad Institute GDAC (https://gdac.broadinstitute.org/). The GISTIC2
analysis (Mermel, 2012) identified a statistically significant (qo0.25) region of
amplification in chr8 (69506698-146364022). Mean gene-level DNA copy number
measurements were computed and plotted by genomic position.
Correlation analyses. The TCGA clear cell renal cell carcinoma (KIRC) and
papillary renal cell carcinoma (KIRP) RNASeq expression datasets were down-
loaded through the Broad Institure pipeline (Broad Institute TCGA Genome Data
Analysis Center (2016): Aggregate Analysis Features. Broad Institute of MIT and
Harvard). Human homologues were identified for mouse genes from the Jackson
Laboratory Mouse Genome Informatics database (http://www.informatics.jax.org/
homology.shtml). When combining datasets, batch effects were adjusted for
using the SVA (surrogate variable analysis) R package version 3.12.0. Centroids
were derived by taking the median expression of each gene across samples in a
designated sample cohort. Centroid similarity metrics were derived by calculating
the Pearson correlation between centroids. Heatmap clustering was done using
centred average linkage clustering on all expressed genes in the data set.
Matrigel invasion assay. RCC GEMM cell lines were plated in serum-free
medium for 24 h. A total of 50,000 cells were seeded into an 8-mm matrigel
chamber (BD Biosciences) and placed in wells containing medium containing 10%
FBS. Cells were allowed to invade for 24 h. Cells that had invaded through
the matrigel were then stained with the Siemens Staining Kit according to
manufacturer’s directions. Matrigel wells were then placed on a glass slide and
analysed and photographed using an Olympus IX51 microscope. Representative
pictures were taken of each matrigel well quadrant, and the number of cells that
had invaded into the matrigel was determined by counting the number of stained
nuclei using ImageJ.
Data availability. Raw RNA sequencing data are available from NCBI GEO under
accession no. GSE97654.
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